Millions of people with #diabetes are affected by diabetic peripheral neuropathy pain (DPNP) which severely diminishes their quality of life. These patients commonly experience burning pain, sleep disturbance, and sensitivity to touch. This article highlights LX-9211, our investigational treatment and its potential effectiveness in reducing pain. We are committed to advancing our research to deliver a novel treatment option for patients who suffer from this condition. Read the article here: https://lnkd.in/gCJ9kWJn #neuropathicpain #DPNP
Lexicon Pharmaceuticals, Inc.
Pharmaceutical Manufacturing
The Woodlands, TX 20,822 followers
At Lexicon, We Pioneer Medicines that Transform Patients' Lives
About us
Corporate Overview Lexicon Pharmaceuticals is a biopharmaceutical company that has harnessed the power of genetics for drug discovery. Our research team has generated a pipeline of novel drug candidates in clinical development across a broad range of indications. The Genome: Our Source of Discovery We have applied gene knockout technology to thousands of potential drug targets encoded in the human genome. Our scientists have gained a thorough understanding of target biology and identified new points of intervention for future therapies. We have integrated a series of recombinant DNA and chemistry technologies into a systematic drug discovery and development process. Our unique knowledge of targets from the human genome has allowed us to better evaluate and advance novel drug candidates with great promise for patients. A Diverse Pipeline of Targeted Therapies Our genomics-based approach to drug discovery has enabled our scientists to select drug targets across a broad range of indications with high unmet medical need. All of our drug candidates are new molecular entities discovered internally by our dedicated drug discovery teams and designed to affect particular points on a genetically-defined pathway that can be used to fight a disease process. We have advanced new therapies across a wide spectrum of human disease, from conditions affecting millions of people, such as diabetes, to carcinoid syndrome, an orphan cancer indication with few treatment options.
- Website
-
http://www.lexpharma.com/
External link for Lexicon Pharmaceuticals, Inc.
- Industry
- Pharmaceutical Manufacturing
- Company size
- 51-200 employees
- Headquarters
- The Woodlands, TX
- Type
- Public Company
- Founded
- 1995
- Specialties
- biopharma, knockout, novel drug, innovation, disease, and pharmaceutical
Locations
-
Primary
8800 Technology Forest
The Woodlands, TX 77381, US
-
-
110 Allen Rd
Basking Ridge, NJ 07920, US
Employees at Lexicon Pharmaceuticals, Inc.
-
Paul Chen
Executive Leadership: Global Market Access | Payer Relations | Managed Markets | Channel & Distribution Strategies
-
Paul Monville
-
Frank Palantoni
Investor, New Ventures
-
Melinda (Thiel) Francini
Vice President, Commercial Strategy & Innovation | Pacesetting health care executive with expertise across the healthcare ecosystem
Updates
-
Lexicon is gearing up for a busy December with participation in three upcoming healthcare investor conferences. Tune into our presentations or find the replays on our Events page: www.lexpharma.com/events #LexiconNews
-
Lexicon is pleased to announce we’ve completed enrollment of our Phase 2b PROGRESS study evaluating our investigational therapy for diabetic peripheral neuropathic pain (DPNP). The study has successfully enrolled 20 percent more patients than originally targeted, highlighting the significant interest and need for new, non-opioid options to address this challenging condition. Learn more: https://lnkd.in/eTmSGpm3 #LexiconNews
-
We're excited to be at the Jefferies 2024 London Healthcare Conference on Wednesday, November 20. Find our webcast details here: https://lnkd.in/giefs2NC #LexiconNews
-
Thank you to Breakthrough T1D for the opportunity to support the #Diabetes community at the 51st Greater New York Metro Promise Gala last week. We’re inspired by your work to advance research and access to care for people with diabetes and are proud to support such a mission.
-
Craig Granowitz, our Chief Medical Officer, offers his perspective on how World Diabetes Day reminds us of the daily challenges that the frequently overlooked people with Type 1 Diabetes face, and their need for treatment options.
People with Type 1 Diabetes - a frequently overlooked population - need more options to cope with the daily challenges of their disease. World Diabetes Day on Thursday, is a good opportunity to think about how to improve their health. #WorldDiabetesDay #T1D
-
In honor of #WorldDiabetesDay, we were at the Breakthrough T1D Greater New York Promise Metro Gala last night to show our support for people with #Diabetes and to champion research breakthroughs for this community.
-
On #WorldDiabetesDay, we are proud to stand with nearly one in ten adults worldwide living with diabetes. At Lexicon, we recognize the challenges of this 24/7 disease and are driven to alleviate some of this burden. Through collaboration with the diabetes community, we strive to deliver new treatment possibilities, better care, and hope.
-
#AHA24 Scientific Sessions are around the corner! Visit our oral presentations, moderated posters and poster presentations on November 16 & 17 to learn more about the latest data from our SGLT1/2 inhibitor program for patients with #HeartFailure. Read more: https://lnkd.in/eYi6prwq #LexiconNews
-
Today is #WorldDiabetesDay! We were thrilled to join the #Diabetes community at Breakthrough T1D walks around the country. Thank you to all who participated. Together, we’re making strides towards a healthier future.
Similar pages
Browse jobs
Stock
LXRX
NASDAQ
20 minutes delay
$0.78
0.039 (5.227%)
- Open
- 0.721
- Low
- 0.721
- High
- 0.799
Data from Refinitiv
See more info on